Review of hypersensitivity reactions to antineoplastic agents;Revisión de las reacciones de hipersensibilidad a antineoplásicos

Farmacia Hospitalaria

Volumn 36, Issue 3, 2012, Pages 148-158

  Cortijo Cascajares, S ^a   Jimenez Cerezo M J ^a   Herreros De Tejada, A ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Antineoplastic agent; Asparaginase; Desensitisation; Hypersensitivity; Platinum salts; Taxanes

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; EPIPODOPHYLLOTOXIN; MONOCLONAL ANTIBODY; PLATINUM DERIVATIVE; TAXANE DERIVATIVE;

ARTICLE; CLINICAL FEATURE; DISEASE COURSE; DRUG HYPERSENSITIVITY; EMBASE; HUMAN; MEDLINE; SYSTEMATIC REVIEW;

EID: 84862145631     PISSN: 11306343     EISSN: 21718695     Source Type: Journal    
DOI: 10.1016/j.farma.2011.02.004     Document Type: Short Survey

References (105)

1. E. Syrigou, N. Makrilia, I. Koti, M.W. Saif, and K.N. Syrigos Hypersensitivity reactions to antineoplastic agents: an overview Anticancer Drugs 20 2009 1 6
2. Holmes B. Chemotherapy-induced hypersensitivity reactions. Oncology nursing forum. Onc Nurs Society. 2005;32:1027-35.
3. G.M. Shepherd Hypersensitivity reactions to chemotherapeutic drugs Clin Rev in Allergy Immunol 24 2003 253 262 (Pubitemid 36584220)
4. M. Pagani The Complex Clinical Picture of Presumably Allergic Side Effects to Cytostatic Drugs: Symptoms, Pathomechanism, Reexposure, and Desensitization Med Clin North Am 94 2010 835 852
5. D.A. Khan, and R. Solensky Drug allergy J Allergy Clin Immunol 125 2010 126 137
6. National Cancer Institute. Common Terminology Criteria for Adverse Events v 3.0 (CTCAE) 2006 [citado 17 Ene 2011]. Disponible en: http://ctep.cancer.gov/ protocoldevelopment/electronic-applications/docs/ctcaev3.pdf.
7. H.J. Lenz Management and preparedness for infusion and hypersensitivity reactions Oncologist 12 2007 601 609
8. M.C. Castells Hypersensitivity to antineoplastic agents Curr Pharm Des 14 2008 2892 2901
9. M. Castells Rapid desensitization for hypersensitivity reactions to medications Immunol Allergy Clin North Am 29 2009 585 606
10. R.B. Weiss, and S. Bruno Hypersensitivity reactions to cancer chemotherapeutic agents Ann Intern Med 94 1981 66 72 (Pubitemid 11218736)
11. R. Basu, A. Rajkumar, and N.R. Datta Anaphylaxis to cisplatin following nine previous uncomplicated cycles Int J Clin Oncol 7 2002 365 367 (Pubitemid 36077320)
12. S. Sliesoraitis, and P.J. Chikhale Carboplatin hypersensitivity Int J Gynecol Cancer 15 2005 13 18 (Pubitemid 40194327)
13. E. Syrigou, N. Makrilia, A. Vassias, I. Nikolaidis, V. Xyla, and L. Manolopoulos Administration of cisplatin in three patients with carboplatin hypersensitivity: is skin testing useful? Anticancer Drugs 21 2010 333 338
14. M. Markman, K. Zanotti, B. Kulp, G. Peterson, and M. Markman Relationship between a history of systemic allergic reactions and risk of subsequent carboplatin hypersensitivity Gynecol Oncol 89 2003 514 516 (Pubitemid 36687801)
15. H. Sugimoto, T. Iwamoto, Y. Murashima, T. Tabata, N. Sagawa, and M. Okuda Risk factors contributing to the development of carboplatin-related delayed hypersensitivity reactions in Japanese patients with gynecologic cancers Cancer Chemother Pharmacol 67 2011 415 419
16. J.R. Schwartz, C. Bandera, A.M. Bradley, L. Brard, R. Legare, and C.O. Granai Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin?. The experience from Women and Infants' Hospital Gynecol Oncol 105 2007 81 83 (Pubitemid 46441444)
17. A. Gadducci, R. Tana, G. Teti, G. Zanca, A. Fanucchi, and A.R. Genazzani Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer Int J Gynecol Cancer 18 2008 615 620 (Pubitemid 352020152)
18. M. Markman, A. Kennedy, K. Webster, P. Elson, G. Peterson, and B. Kulp Clinical features of hypersensitivity reactions to carboplatin J Clin Oncol 17 1999 1141 1145 (Pubitemid 29162937)
19. M. Navo, A. Kunthur, M.L. Badell, I.I. Coffer, W. Larry, and M. Markman Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients Gynecol Oncol 103 2006 608 613 (Pubitemid 44602175)
20. B. Weidmann, N. Mülleneisen, P. Bojko, and N. Niederle Hypersensitivity reactions to carboplatin. Report of two patients, review of the literature, and discussion of diagnostic procedures and management Cancer 73 1994 2218 2222 (Pubitemid 24107980)
21. D. Winkeljohn, and M. Polovich Carboplatin Hypersensitivity Reactions Clin J Oncol Nurs 10 2006 595 598
22. A. Polyzos, N. Tsavaris, C. Kosmas, T. Arnaouti, N. Kalahanis, and C. Tsigris Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience Oncology 61 2000 129 133 (Pubitemid 32786206)
23. A. Polyzos, N. Tsavaris, H. Gogas, J. Souglakos, L. Vambakas, and N. Vardakas Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience Oncology 76 2008 36 41
24. M.W. Saif Hypersensitivity reactions associated with oxaliplatin Expert Opin Drug Saf 5 2006 687 694
25. B.H. Kim, T. Bradley, J. Tai, and D.R. Budman Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review Oncology 76 2009 231 238
26. J. Medioni, M.A. Coulon, J.F. Morere, F. Hennebelle, S. Piperno-Neumann, and J.L. Breau Anaphylaxis after oxaliplatin Ann Oncol 10 1999 610
27. M.Y. Lee, M.H. Yang, J.H. Liu, C.C. Yen, P.C. Lin, and H.W. Teng Severe anaphylactic reactions in patients receiving oxaliplatin therapy: a rare but potentially fatal complication Support Care Cancer 15 2007 89 93
28. S. Potenza, G. Nasti, O. Alessandro, A. Filippelli, F. Rossi, and A. Capuano Severe respiratory symptoms to oxaliplatin infusion: a case report of delayed hypersensitivity reaction Invest New Drugs 28 2010 185 186
29. C. Köhlmoos, G.G. Marquardt, D. Brinkmann, and K. Meier Allergic reactions to oxaliplatin therapy-an overview European Journal of Oncology Pharmacy 2 2008 27 28
30. R.S. De Vries, E.J. Mattijssen, and A.A. van Sorge Serious delayed hypersensitivity reaction to oxaliplatin Ann Oncol 17 2006 1723 1724 (Pubitemid 44680899)
31. S. Siu, R. Chan, and G. Au Hypersensitivity reactions to oxaliplatin: experience in a single institute Ann Oncol 17 2006 259
32. E.I. Syrigou, E.M. Karapanagiotou, C.V. Alamara, P.G. Boura, M.W. Saif, and K.N. Syrigos Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol Clin colorectal cancer 8 2009 106 109
33. Y.Y. Shao, F.C. Hu, J.T. Liang, W.T. Chiu, A.L. Cheng, and C.H. Yang Characteristics and Risk Factors of Oxaliplatin-related Hypersensitivity Reactions J Formosan Med Assoc 109 2010 362 368
34. K.H. Lee, Y.J. Park, E.S. Kim, H.J. Hwang, B.Y. Shim, and H.K. Kim Hypersensitivity reactions to oxaliplatin Cancer Res Treat 38 2006 240 241
35. G. Brandi, M. Pantaleo, C. Galli, A. Falcone, A. Antonuzzo, and P. Mordenti Hypersensitivity reactions related to oxaliplatin (OHP) Br J Cancer 89 2003 477 481 (Pubitemid 37026428)
36. P. Bhargava, D. Gammon, and M.J. McCormick Hypersensitivity and idiosyncratic reactions to oxaliplatin Cancer 100 2004 211 212
37. C.V.T. Ng Hypersensitivity reactions to oxaliplatin in two Asian patients Ann Pharmacother 39 2005 1114 1118 (Pubitemid 40695981)
38. R.R. Thomas, M.G. Quinn, B. Schuler, and J.L. Grem Hypersensitivity and idiosyncratic reactions to oxaliplatin Cancer 97 2003 2301 2307 (Pubitemid 36444076)
39. D.P. Greene, J.S. Ferriss, and A.A. Jazaeri Cisplatin administration following carboplatin desensitization failure in primary peritoneal cancer: a brief report Cancer Chemother Pharmacol 66 2010 265 267
40. M.B. Callahan, J.A. Lachance, R.L. Stone, J. Kelsey, L.W. Rice, and A.A. Jazaeri Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer Am J Obstet Gynecol 197 2007 199
41. M.J. Kandel, A. Loehr, P. Harter, A. Traut, and K. Gnauert Cisplatinum rechallenge in relapsed ovarian cancer patients with platinum reinduction therapy and carboplatin hypersensitivity Int J Gynecol Cancer 15 2005 780 784 (Pubitemid 41783081)
42. A. Abe, H. Ikawa, and S. Ikawa Desensitization treatment with cisplatin after carboplatin hypersensitivity reaction in gynecologic cancer J Med Invest 57 2010 163 167
43. D.S. Dizon, P.J. Sabbatini, C. Aghajanian, M.L. Hensley, and D.R. Spriggs Analysis of Patients with Epithelial Ovarian Cancer or Fallopian Tube Carcinoma Retreated with Cisplatin after the Development of a Carboplatin Allergy Gynecol Oncol 84 2002 378 382 (Pubitemid 34211861)
44. S. Zweizig, I. Romanand Laila, and D. Lynda Death from anaphylaxis to cisplatin: a case report Gynecol Oncol 53 1994 121 122 (Pubitemid 24136913)
45. L. Meyer, T. Zuberbier, M. Worm, H. Oettle, and H. Riess Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule J Clin Oncol 20 2002 1146 1147 (Pubitemid 34141861)
46. V. Leguy-Seguin, G. Jolimoy, B. Coudert, C. Pernot, S. Dalac, and P. Vabres Diagnostic and predictive value of skin testing in platinum salt hypersensitivity J Allergy Clin Immunol 119 2007 726 730
47. M. Markman, K. Zanotti, G. Peterson, B. Kulp, K. Webster, and J. Belinson Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity J Clin Oncol 21 2003 4611 4614 (Pubitemid 46594035)
48. K. Zanotti, L. Rybicki, A. Kennedy, J. Belinson, K. Webster, and B. Kulp Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy J Clin Oncol 19 2001 3126 3129 (Pubitemid 32565451)
49. R. Gomez, P. Harter, H.J. Lück, A. Traut, S. Kommoss, and M. Kandel Carboplatin Hypersensitivity: Does Introduction of Skin Test and Desensitization Reliably Predict and Avoid the Problem?. A Prospective Single-Center Study Int J Gynecol Cancer 19 2009 1284 1287
50. T. Herrero, P. Tornero, S. Infante, V. Fuentes, M. Sanchez, and M. De Barrio Diagnosis and management of hypersensitivity reactions caused by oxaliplatin J Investig Allergol Clin Immunol 16 2006 327 330 (Pubitemid 44580263)
51. C. Garufi, A. Cristaudo, B. Vanni, E. Bria, A.M. Aschelter, and B. Santucci Skin testing and hypersensitivity reactions to oxaliplatin Ann Oncol 14 2003 497 498 (Pubitemid 36367431)
52. M. Castells Desensitization for drug allergy Curr Opin Allergy Clin Immunol 6 2006 476 481 (Pubitemid 44714163)
53. T. Limsuwan, and M.C. Castells Outcomes and safety of rapid desensitization for chemotherapy hypersensitivity Expert Opin Drug Saf 9 2010 39 53
54. C.W. Lee, U.A. Matulonis, and M.C. Castells Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions Gynecol Oncol 95 2004 370 376 (Pubitemid 39445874)
55. M. Castells Rapid Desensitization of Hypersensitivity Reactions to Chemotherapy Agents Curr Drug Saf 1 2006 243 251
56. C.W. Lee, U.A. Matulonis, and M.C. Castells Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses Gynecol Oncol 99 2005 393 399 (Pubitemid 41502850)
57. J.B. Robinson, D. Singh, D.C. Bodurka-Bevers, J.T. Wharton, D.M. Gershenson, and J.K. Wolf Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies Gynecol Oncol 82 2001 550 558 (Pubitemid 32826458)
58. M.C. Castells, N.M. Tennant, D.E. Sloane, F. Ida Hsu, N.A. Barrett, and D.I. Hong Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensitization in 413 cases J Allergy Clin Immunol 122 2008 574 580
59. H. Nozawa, Y. Muto, and Y. Yamada Desensitization to oxaliplatin with two stages of premedication in a patient with metastatic rectal cancer Clin Ther 30 2008 1160 1165 (Pubitemid 351978121)
60. L. Mis, N.H. Fernando, H.I. Hurwitz, and M.A. Morse Successful desensitization to oxaliplatin Ann Pharmacother 39 2005 966 969 (Pubitemid 40570680)
61. D. Gammon, P. Bhargava, and M.J. McCormick Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol Oncologist 9 2004 546 549 (Pubitemid 39332318)
62. D.A. Edmondson, B.J. Gruling, A.M. Urmanski, S.J. Wong, and M.B. Levy Oxaliplatin hypersensitivity: case report and successful repeat desensitization Am J Ther 14 2007 116 118 (Pubitemid 46278673)
63. S. Nishio, T. Koyanagi, K. Miyabe, and H. Kuromatsu Successful desensitization protocol for patients with hypersensitivity reactions caused by carboplatin Gan To Kagaku Ryoho 37 2010 731 733
64. R. Confino-Cohen, A. Fishman, M. Altaras, and A. Goldberg Successful carboplatin desensitization in patients with proven carboplatin allergy Cancer 104 2005 640 643 (Pubitemid 41022823)
65. P.G. Rose, N. Fusco, M. Smrekar, K. Mossbruger, and M. Rodriguez Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity Gynecol Oncol 89 2003 429 433 (Pubitemid 36687788)
66. M. Markman, F. Hsieh, K. Zanotti, K. Webster, G. Peterson, and B. Kulp Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions J Cancer Res Clin Oncol 130 2004 25 28 (Pubitemid 38161244)
67. J. Choi, P. Harnett, and D.A. Fulcher Carboplatin desensitization Ann Allergy Asthma Immunol 93 2004 137 141 (Pubitemid 39128492)
68. M. Markman, A. Kennedy, K. Webster, B. Kulp, G. Peterson, and J. Belinson Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center J Clin Oncol 18 2000 102 105 (Pubitemid 30036342)
69. C. Lee, M. Gianos, and W.B. Klaustermeyer Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents Ann Allergy Asthma Immunol 102 2009 179 187
70. R.B. Weiss, R.C. Donehower, P.H. Wiernik, T. Ohnuma, R.J. Gralla, and D.L. Trump Hypersensitivity reactions from taxol J Clin Oncol 8 1990 1263 1268 (Pubitemid 20195638)
71. A. Prieto, and F. Pineda Immunoglobulin E-Mediated Severe Anaphylaxis to Paclitaxel J Investig Allergol Clin Immunol 20 2010 170 176
72. A.J. Tije, J. Verweij, W.J. Loos, and A. Sparreboom Pharmacological effects of formulation vehicles: implications for cancer chemotherapy Clin Pharmacokinet 42 2003 665 685 (Pubitemid 36936530)
73. A.N. Fader, and P.G. Rose Abraxane for the Treatment of Gynecologic Cancer Patients With Severe Hypersensitivity Reactions to Paclitaxel Int J Gynecol Cancer 19 2009 1281 1283
74. Paclitaxel hypersensitivity reactions: Prevalence and outcomes. J Clin Oncol 2010; 28 (15-suppl): Abstract 16518.
75. J.K. Olson, A.K. Sood, J.I. Sorosky, B. Anderson, and R.E. Buller Taxol hypersensitivity: rapid retreatment is safe and cost effective Gynecol Oncol 68 1998 25 28 (Pubitemid 28109818)
76. A.M. Feldweg, C.W. Lee, U.A. Matulonis, and M. Castells Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments Gynecol Oncol 96 2005 824 829 (Pubitemid 40255508)
77. A. Fishman, T. Gold, A. Goldberg, R. Confino-Cohen, Y. Beyth, and J. Menczer Effective desensitization protocol to paclitaxel following hypersensitivity reaction Int J Gynecol Cancer 9 1999 156 159 (Pubitemid 29220754)
78. S. Isonishi, M. Suzuki, M. Hirama, R. Matsumoto, K. Ochiai, and T. Tanaka Use of Docetaxel After Paclitaxel Hypersensitivity Reaction in Epithelial Ovarian and Endometrial Cancer Clin Ovarian Cancer 2 2009 44 47
79. C. Moon, C.F. Verschraegen, M. Bevers, R. Freedman, A.P. Kudelka, and J.J. Kavanagh Use of docetaxel (Taxotere (R)) in patients with paclitaxel (Taxol (R)) hypersensitivity Anticancer Drugs 11 2000 565 568
80. J. Lokich, and N. Anderson Paclitaxel hypersensitivity reactions: A role for docetaxel substitution Ann Oncol 9 1998 573 574 (Pubitemid 28270648)
81. D.S. Dizon, J. Schwartz, A. Rojan, J. Miller, L. Pires, and P. DiSilvestro Cross-sensitivity between paclitaxel and docetaxel in a women's cancers program Gynecol Oncol 100 2006 149 151 (Pubitemid 41815065)
82. J.P. Micha, B.H. Goldstein, C.L. Birk, M.A. Rettenmaier, and J.V. Brown III Abraxane in the treatment of ovarian cancer: the absence of hypersensitivity reactions Gynecol Oncol 100 2006 437 438 (Pubitemid 43075284)
83. W.J. Gradishar, S. Tjulandin, N. Davidson, H. Shaw, N. Desai, and P. Bhar Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer J Clin Oncol 23 2005 7794 7803 (Pubitemid 46657376)
84. U.K. Narta, S.S. Kanwar, and W. Azmi Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia Crit Rev Oncol Hematol 61 2007 208 221 (Pubitemid 46329425)
85. L.M. Vrooman, J.G. Supko, D.S. Neuberg, B.L. Asselin, U.H. Athale, and L. Clavell Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia Pediatr Blood Cancer 54 2010 199 205
86. A.L. Billett, S.E. Sallan, A. Carls, and R.D. Gelber Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase Cancer 70 1992 201 206
87. L. Hernández, A. Álvarez, N. Gómez, I. Castorena, Á. Pedroza, and J.G. Huerta Desensibilización para L-asparaginasa. Reporte de un caso en hospital de tercer nivel Alergia, Asma e Inmunología 18 2009 121 125
88. F. Marín, M.T. Carmona, A. Toledo, A. Salas, B. Oya, and J.M. Ramírez Desensibilización a L-asparraginasa en dos pacientes con hipersensibilidad previa Farm Hosp 30 2006 130 135
89. O.U. Soyer, S. Aytac, A. Tuncer, M. Cetin, S. Yetgin, and B.E. Sekerel Alternative algorithm for L-asparaginase allergy in children with acute lymphoblastic leukemia J Allergy Clin Immunol 123 2009 895 899
90. A. Alvarez-Cardona, L. Hernandez-Nieto, M. Perez-Gómez, and Á. Pedroza-Melendez Desensibilización para etopósido. Comunicación de un caso Revista Alergia México 57 2010 33 36
91. B.J. Bernstein, and M.B. Troner Successful rechallenge with etoposide phosphate after an acute hypersensitivity reaction to etoposide Pharmacotherapy 19 1999 989 991 (Pubitemid 29377318)
92. C.H. Chung Managing premedications and the risk for reactions to infusional monoclonal antibody therapy Oncologist 13 2008 725 732 (Pubitemid 351904917)
93. W.H. Vogel Infusion Reactions Clin J Oncol Nurs 14 2010 10 21
94. E. Maggi, A. Vultaggio, and A. Matucci Acute infusion reactions induced by monoclonal antibody therapy Expert Rev Clin Immunol 7 2011 55 63
95. C.H. Chung, B. Mirakhur, E. Chan, Q.T. Le, J. Berlin, and M. Morse Cetuximab-induced anaphylaxis and IgE specific for galactose-{alpha}-1, 3-galactose N Engl J Med 358 2008 1109 1117 (Pubitemid 351398485)
96. G. Calogiuri, M.T. Ventura, L. Mason, A. Valacca, R. Buquicchio, and N. Cassano Hypersensitivity reactions to last generation chimeric, humanized [correction of umanized] and human recombinant monoclonal antibodies for therapeutic use Curr Pharm Des 14 2008 2883 2891
97. O.V. Hausmann, M. Seitz, P.M. Villiger, and W.J. Pichler The Complex Clinical Picture of Side Effects to Biologicals Med Clin North Am 94 2010 791 804
98. T.T. Hansel, H. Kropshofer, T. Singer, J.A. Mitchell, and A.J.T. George The safety and side effects of monoclonal antibodies Nat Rev Drug Disc 9 2010 325 338
99. J. Timoney, K.Y. Chung, and V. Park Cetuximab use without chronic antihistamine premedication J Clin Oncol 24 suppl 18 2006 Abstract 13521
100. S.P. Kang, and M.W. Saif Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer - identification, prevention, and management J Support Oncol 5 2007 451 457 (Pubitemid 350031835)
101. M.R. Jerath, M. Kwan, M. Kannarkat, B. Mirakhur, L. Carey, and J. Valgus A desensitization protocol for the mAb cetuximab J Allergy Clin Immunol 123 2009 260 262
102. P.J. Brennan, T.R. Bouza, F.I. Hsu, D.E. Sloane, and M.C. Castells Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment J Allergy Clin Immunol 124 2009 1259 1266
103. W. Brugger Successful treatment with the fully human antibody panitumumab after a severe infusion reaction with cetuximab Tumori 96 2010 473 477
104. D.G. Power, M.A. Shah, T.R. Asmis, J.J. Garcia, and N.E. Kemeny Safety and efficacy of panitumumab following cetuximab: retrospective review of the Memorial Sloan-Kettering experience Invest New Drugs 28 2010 353 360
105. M.W. Saif, K.I. Syrigos, S. Hotchkiss, J. Shanley, J. Grasso, and T.M. Ferencz Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer Cancer Chemother Pharmacol 65 2009 107 112